US Pharma MarketingParabilis CEO Mathai Mammen on biotech's record IPO
Parabilis Medicines CEO Mathai Mammen speaks about the biotech Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation…
Parabilis Medicines cemented the largest biotech IPO in industry history on Wednesday with its $670 million debut on the Nasdaq.
But the Cambridge, MA-based drug developer won't be celebrating at the listing exchange in Times ...
Source: Endpoints News